<DOC>
	<DOC>NCT01791699</DOC>
	<brief_summary>Hypothesis: Modulation of central nervous sympathetic activation by administration of moxonidine, a centrally acting medication which decreases the sympathetic nervous system activity, can lead to a decrease in atrial fibrillation recurrence after ablation treatment with pulmonary vein isolation.</brief_summary>
	<brief_title>Moxonidine for Prevention of Post-ablation AFib Recurrences</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Moxonidine</mesh_term>
	<criteria>Hypertensive patients with paroxysmal atrial fibrillation. At least two documented episodes within the last 12 months (either selfterminating within 7 days or cardioverted, medically or electrically, in less than 48 hours). At least one episode should have been documented under treatment with a class Ic or III antiarrhythmic drug. 1. age &lt;25 or &gt;80 years 2. presence of atrial thrombus 3. left atrial volume index &gt;55 ml/m2 4. hypersensitivity to moxonidine 5. sick sinus syndrome or sinoatrial block 6. 2nd or 3rd degree atrioventricular block 7. bradycardia (below 50 beats/minute at rest) 8. estimated glomerular filtration rate &lt;40 ml/min/1.73 m2 9. history of angioneurotic oedema 10. heart failure symptoms OR impaired left ventricular function (EF &lt;40%), even if asymptomatic 11. stable or unstable angina pectoris 12. intermittent claudication or known peripheral artery disease 13. Parkinson's disease 14. epileptic disorders 15. glaucoma 16. history of depression 17. pregnancy or lactation 18. inability or unwillingness to adhere to standard treatment or to provide consent.</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>atrial fibrillation</keyword>
	<keyword>paroxysmal</keyword>
	<keyword>persistent</keyword>
	<keyword>ablation</keyword>
	<keyword>pulmonary vein isolation</keyword>
	<keyword>recurrence</keyword>
</DOC>